Given the great differences in inherent behaviors and clinical outcomes of this subtype breast cancer, the HR-associated heterogeneity should be fully considered in the course of therapeutic strategies introduction and cancer management for HER2-positive breast cancer in clinical practice. The gene discussed is ERBB2; the disease is breast carcinoma.